PURPOSE: Management of prostate cancer following radiation therapy remains challenging, especially for younger men or those with life expectancy greater than 10 years. We outline the efficacy, safety and adequacy of radical prostatectomy for the treatment of radiorecurrent localized prostate cancer. METHODS: A systematic review was performed in September 2012 searching MEDLINE articles from 1980 to 2012 on salvage radical prostatectomy. We excluded unpublished data and non-English-language articles. RESULTS: The ideal candidate for salvage radical prostatectomy (SRP) has a life expectancy greater than 10 years, a PSA < 10 ng/ml and whose initial clinical staging was T1 or T2. A prostate biopsy and imaging studies to rule out metastatic disease should be performed prior to SRP. Salvage RP has a high complication rate, but this appears to be decreasing over time. Urinary continence rates range from 36 to 81%, whereas erectile function following SRP was generally poor with less than 30% of men regaining adequate erectile function. Men with good erectile function prior to SRP fared better than those with pre-operative erectile dysfunction. Biochemical recurrence-free probability at 5 years ranged from 37 to 55% and the estimated cancer-specific survival at 10 years ranged from 70 to 83%. Minimally invasive SRP is feasible and early outcomes suggest that this approach is not inferior to open surgery. CONCLUSION: SRP offers a potentially curative option with proven long-term disease-free survival in appropriately selected patients. Given the morbidity of this procedure, judicious patient selection and referral to providers experienced with salvage surgery may optimize patient outcomes.
PURPOSE: Management of prostate cancer following radiation therapy remains challenging, especially for younger men or those with life expectancy greater than 10 years. We outline the efficacy, safety and adequacy of radical prostatectomy for the treatment of radiorecurrent localized prostate cancer. METHODS: A systematic review was performed in September 2012 searching MEDLINE articles from 1980 to 2012 on salvage radical prostatectomy. We excluded unpublished data and non-English-language articles. RESULTS: The ideal candidate for salvage radical prostatectomy (SRP) has a life expectancy greater than 10 years, a PSA < 10 ng/ml and whose initial clinical staging was T1 or T2. A prostate biopsy and imaging studies to rule out metastatic disease should be performed prior to SRP. Salvage RP has a high complication rate, but this appears to be decreasing over time. Urinary continence rates range from 36 to 81%, whereas erectile function following SRP was generally poor with less than 30% of men regaining adequate erectile function. Men with good erectile function prior to SRP fared better than those with pre-operative erectile dysfunction. Biochemical recurrence-free probability at 5 years ranged from 37 to 55% and the estimated cancer-specific survival at 10 years ranged from 70 to 83%. Minimally invasive SRP is feasible and early outcomes suggest that this approach is not inferior to open surgery. CONCLUSION: SRP offers a potentially curative option with proven long-term disease-free survival in appropriately selected patients. Given the morbidity of this procedure, judicious patient selection and referral to providers experienced with salvage surgery may optimize patient outcomes.
Authors: Daher C Chade; Shahrokh F Shariat; Angel M Cronin; Caroline J Savage; R Jeffrey Karnes; Michael L Blute; Alberto Briganti; Francesco Montorsi; Henk G van der Poel; Hendrik Van Poppel; Steven Joniau; Guilherme Godoy; Antonio Hurtado-Coll; Martin E Gleave; Marcos Dall'Oglio; Miguel Srougi; Peter T Scardino; James A Eastham Journal: Eur Urol Date: 2011-03-21 Impact factor: 20.096
Authors: Andrew J Stephenson; Peter T Scardino; Fernando J Bianco; Christopher J DiBlasio; Paul A Fearn; James A Eastham Journal: J Urol Date: 2004-12 Impact factor: 7.450
Authors: Ronald S Boris; Akshay Bhandari; L Spencer Krane; Daniel Eun; Sanjeev Kaul; James O Peabody Journal: BJU Int Date: 2008-12-02 Impact factor: 5.588
Authors: G L Grado; J M Collins; J S Kriegshauser; C S Balch; M M Grado; G P Swanson; T R Larson; M M Wilkes; R J Navickis Journal: Urology Date: 1999-01 Impact factor: 2.649
Authors: Jonathan A Eandi; Brian A Link; Rebecca A Nelson; David Y Josephson; Clayton Lau; Mark H Kawachi; Timothy G Wilson Journal: J Urol Date: 2010-01 Impact factor: 7.450
Authors: Piyush K Agarwal; Natalia Sadetsky; Badrinath R Konety; Martin I Resnick; Peter R Carroll Journal: Cancer Date: 2008-01-15 Impact factor: 6.860
Authors: Khurram M Siddiqui; Michele Billia; Andrew Williams; Ali Alzahrani; Joseph L Chin Journal: Can Urol Assoc J Date: 2015 Sep-Oct Impact factor: 1.862
Authors: Shalini Moningi; Ethan B Ludmir; Praveen Polamraju; Tyler Williamson; Marcella M Melkun; Joseph D Herman; Sunil Krishnan; Eugene J Koay; Albert C Koong; Bruce D Minsky; Grace L Smith; Cullen Taniguchi; Prajnan Das; Emma B Holliday Journal: Clin Transl Radiat Oncol Date: 2019-08-27
Authors: Catarina Dinis Fernandes; Ghazaleh Ghobadi; Henk G van der Poel; Jeroen de Jong; Stijn W T P J Heijmink; Ivo Schoots; Iris Walraven; Petra J van Houdt; Milena Smolic; Floris J Pos; Uulke A van der Heide Journal: Eur Radiol Date: 2018-11-12 Impact factor: 5.315